Dihydropyrimidine Dehydrogenase Deficiency and Fluorouracil-Related Toxicity
Author Information
Author(s): Milano G, Etienne M C, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N
Primary Institution: Centre Antoine Lacassagne
Hypothesis
Women may be more prone to dihydropyrimidine dehydrogenase deficiency and related toxicity from 5-fluorouracil chemotherapy.
Conclusion
The study found that women are particularly prone to DPD deficiency, which is associated with severe toxicity from 5-FU treatment.
Supporting Evidence
- 19 out of 53 patients had significant DPD deficiency.
- The majority of patients with DPD deficiency were women.
- Toxicity scores were higher in patients with marked DPD deficiency.
Takeaway
This study looked at patients who got sick from a cancer drug and found that women are more likely to have a problem with the way their body breaks down the drug.
Methodology
Lymphocyte samples were collected from patients treated with 5-FU-based chemotherapy to determine DPD levels.
Potential Biases
Potential bias due to the selection of patients who experienced toxicity.
Limitations
The study was limited to a specific group of patients from different French institutions.
Participant Demographics
53 patients (23 men, 30 women) with a mean age of 58 years.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website